Standardized Use of the Stanford Integrated Psychosocial Assessment for Transplantation in LVAD Patients.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 02 03 2019
revised: 30 05 2019
accepted: 14 06 2019
pubmed: 21 6 2019
medline: 15 8 2020
entrez: 21 6 2019
Statut: ppublish

Résumé

Increased psychosocial risk portends poor outcomes following heart transplantation. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) is a validated, psychosocial risk assessment tool that helps stratify candidates for transplantation. We assessed the impact of psychosocial factors as measured by the SIPAT on clinical outcomes following left ventricular assist device (LVAD) implantation at our institution. A total of 115 individuals (mean age: 57 years, 75.6% men) who underwent LVAD implantation, for either bridge-to-transplant (63%) or destination therapy, from 2014 to 2016 were included for analysis. Correlations between SIPAT scores, baseline characteristics, and post-LVAD outcomes were assessed through a retrospective correlational design. At 1 year post-LVAD, the higher risk SIPAT group had more emergency department visits, urgent clinic visits, and readmissions in univariate analysis (rate ratio 1.7 [95% confidence interval (CI) 1.0-2.7, P = .035]). After multivariate analysis, this association retained near-statistical significance (rate ratio 1.6 [95% CI 1.0-2.8, P = .051]). There was also a trend toward more device-associated infections (rate ratio 2.1 [95% CI 0.96-4.4, P = .064]). There was no difference in incidence of other adverse events or 1-year mortality between the 2 groups. Higher psychosocial risk per SIPAT in patients undergoing LVAD implantation is associated with more emergency room visits, urgent visits and readmissions over 1 year, but not LVAD-related complications or mortality. Use of the SIPAT tool may help identify patients at higher risk for hospitalization and/or urgent care beyond traditional factors, but should not preclude LVAD implantation.

Sections du résumé

BACKGROUND BACKGROUND
Increased psychosocial risk portends poor outcomes following heart transplantation. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) is a validated, psychosocial risk assessment tool that helps stratify candidates for transplantation. We assessed the impact of psychosocial factors as measured by the SIPAT on clinical outcomes following left ventricular assist device (LVAD) implantation at our institution.
METHODS AND RESULTS RESULTS
A total of 115 individuals (mean age: 57 years, 75.6% men) who underwent LVAD implantation, for either bridge-to-transplant (63%) or destination therapy, from 2014 to 2016 were included for analysis. Correlations between SIPAT scores, baseline characteristics, and post-LVAD outcomes were assessed through a retrospective correlational design. At 1 year post-LVAD, the higher risk SIPAT group had more emergency department visits, urgent clinic visits, and readmissions in univariate analysis (rate ratio 1.7 [95% confidence interval (CI) 1.0-2.7, P = .035]). After multivariate analysis, this association retained near-statistical significance (rate ratio 1.6 [95% CI 1.0-2.8, P = .051]). There was also a trend toward more device-associated infections (rate ratio 2.1 [95% CI 0.96-4.4, P = .064]). There was no difference in incidence of other adverse events or 1-year mortality between the 2 groups.
CONCLUSIONS CONCLUSIONS
Higher psychosocial risk per SIPAT in patients undergoing LVAD implantation is associated with more emergency room visits, urgent visits and readmissions over 1 year, but not LVAD-related complications or mortality. Use of the SIPAT tool may help identify patients at higher risk for hospitalization and/or urgent care beyond traditional factors, but should not preclude LVAD implantation.

Identifiants

pubmed: 31220624
pii: S1071-9164(19)30214-3
doi: 10.1016/j.cardfail.2019.06.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

735-743

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Matthew Cagliostro (M)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Andrew Bromley (A)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Peter Ting (P)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

John Donehey (J)

Mount Sinai Medical Center, New York, New York.

Bart Ferket (B)

The Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.

Kira Parks (K)

Mount Sinai Medical Center, New York, New York.

Elyse Palumbo (E)

Mount Sinai Medical Center, New York, New York.

Donna Mancini (D)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York; Mount Sinai Hospital, The Zena and Michael A. Wiener Cardiovascular Institute, New York, New York.

Anelechi Anyanwu (A)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Amit Pawale (A)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Sean Pinney (S)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York; Mount Sinai Hospital, The Zena and Michael A. Wiener Cardiovascular Institute, New York, New York.

Noah Moss (N)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York; Mount Sinai Hospital, The Zena and Michael A. Wiener Cardiovascular Institute, New York, New York.

Anuradha Lala (A)

Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York; Mount Sinai Hospital, The Zena and Michael A. Wiener Cardiovascular Institute, New York, New York; The Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Anu.lala@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH